Stonehaven Incubate, formed in February 2018, and a dedicated, animal health group committed to creating new companies de novo from disruptive human technology, has appointed Dr Gwynneth Thomas as investment manager based in London.
The Swiss group said Dr Thomas has extensive scientific and commercial experience in the areas of pathology, genomics, digital health, medical device and diagnostics.
Dr Mark Heffernan, CEO of Stonehaven Incubate, said: “Gwynneth has spent her career at the intersection of business and science, gaining significant experience in product growth, operations and fundraising, within, and on behalf of, early-stage human health companies.
"This includes over two years at the Texas Medical Center’s Innovation Institue in Houston, the largest medical center in the world, where she engaged over 50 human health start-up companies with the greater medical community, supporting them as they worked through various strategic business decisions.
“She is ideally suited to the role of Investment Manager here at Stonehaven Incubate where she will be able to help our clients with the creation and growth of new animal health companies.”
Stonehaven has recently announced an alliance with Nuritas, with the collaboration initially focused on feed ingredients.